Vator Securities advises Magle Group in Acquisition of pK Biotech ApS and pK Chemicals

About Magle Chemoswed

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence.

Merger Details  

pK Chemicals, headquartered in Denmark, is a leading player in the global pharmaceutical and medico sectors. Known for its production of technical Dextran and Dextran Derivatives, pK Chemicals has 65 employees and operates two manufacturing sites in Denmark. In 2023, pK Chemicals reported a gross profit of approximately SEK 116 million, with a profit from operating activities of approximately SEK 17 million. 

Merger Benefits  

• The merger will combine resources and expertise, unlocking new growth opportunities and achieving operational efficiencies. The new Magle Group will offer an extensive portfolio covering technical Dextran, Dextran Derivatives, DSM-based innovations, active pharmaceutical ingredients, and customised solutions for the pharmaceutical and medico sectors. Additionally, the increased CDMO capabilities will allow Magle Group to better serve existing and new customers with enhanced development and manufacturing services.


• This combination will significantly expand Magle Group’s contract development and manufacturing organisation (CDMO) capabilities, increasing production capacity and broadening service offerings to meet the growing demand for high-quality development and manufacturing services. 

Website: https://maglegroup.com/